Trump’s FDA Pick Is Speeding Up New Drug Approvals

  • Newsweek | by: Peter J. Pitts |
  • 02/02/2018 12:00 AM
Trump’s FDA Pick Is Speeding Up New Drug Approvals
During his first year as FDA Commissioner, Scott Gottlieb has dramatically reformed the drug approval process. He's made it faster and more transparent and the changes are already bearing fruit.

In 2017, the FDA set an all-time record for generic drug approvals and for more novel drugs than any year since 1996.  

Some analysts say that a quicker generics approval process will hurt innovator pharmaceutical companies. They argue that more drug approvals will force firms to slash prices as they compete for market share. The lost revenue, they say, will more than outweigh any savings from a more enlightened regulatory process.

Such analysts are dead wrong. Drug innovators thrive from competition. What they fear is regulatory uncertainty.

Gottlieb's reforms are making the approval process more predictable. And it's predictability that encourages innovation and investment, which results in both more lifesaving drugs and lower priced generics.

Up until the early 1990s, the FDA's drug approval process was (to be charitable) ambiguous. The agency never clearly signaled how any one investigational new drug would be evaluated. Nor did the FDA specify how long reviews would last.

While this ambiguity protected much-needed flexibility for overworked regulators, it deterred more robust investment in research and development. Drug companies hesitated to spend billions on research projects only to send applications into a black hole.

Drug research is both scientifically difficult and financially taxing. It takes more than a decade and costs well over $2 billion to develop just one FDA-approved drug. 


 
Sign Up for Our Email Newsletter

RECENT NEWS

Unmasking the Real Cost Drivers in U.S. Healthcare: A Critical Examination of Hospital Pricing and Policy Reform

Unmasking the Real Cost Drivers in U.S. Healthcare: A Critical Examination of Hospital Pricing and Policy Reform

From 2000 to 2020, the U.S. saw more than 1,600 hospital mergers. These consolidations have led to decreased competition,...  Read more

The biggest challenge facing the FDA’s new Rare Disease Innovation Hub

The biggest challenge facing the FDA’s new Rare Disease Innovation Hub

Differing philosophies within and outside of government could doom the hub...  Read more

Countries Not Paying Their Fair Share of the Cost of Biopharmaceutical Innovation - What Can the US Do to Change That?
  • RCJ
  • 05/09/2025 12:00 AM

Countries Not Paying Their Fair Share of the Cost of Biopharmaceutical Innovation - What Can the US Do to Change That?

The principal reason for the disparity in biopharmaceutical pricing is that governments in other developed countries use ...  Read more

DRUGWONKS BLOG